Transcription factor TFIIIB component B'' homolog (BDP1)

Homo sapiens — UniProt A6H8Y1

Gene: BDP1Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Transcription factor TFIIIB component B'' homolog (BDP1) is a protein from Homo sapiens identified by UniProt accession A6H8Y1, 2624 residues long. MolForge cross-references it against 0 known binders and 66 disease associations.

UniProt accession: A6H8Y1; gene symbol BDP1.
Organism: Homo sapiens.
Length: 2624 amino acids.
Top disease associations (Open Targets): neurodegenerative disease, hearing loss, autosomal recessive and aspartate aminotransferase measurement.
3D structure: AlphaFold model available.

Target properties

Protein name	Transcription factor TFIIIB component B'' homolog
UniProt accession	A6H8Y1
Gene	BDP1
Organism	Homo sapiens
Length	2624 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (66)

Diseases linked to this target (Open Targets).

neurodegenerative disease · score 0.45
hearing loss, autosomal recessive · score 0.42
aspartate aminotransferase measurement · score 0.33
deafness · score 0.26
Hearing impairment · score 0.12
total blood protein measurement · score 0.12
ovarian serous adenocarcinoma · score 0.07
triple-negative breast cancer · score 0.07
cancer · score 0.06
infection · score 0.05

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-A6H8Y1-F1	alphafold	PREDICTED	36.97	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for A6H8Y1.

Amino-acid sequence (2624 residues)

MFRRARLSVK PNVRPGVGAR GSTASNPQRG RESPRPPDPA TDSASKPAEP TDVPTVDFGG AEPQEKAPRS STEKTGGDND VEESSRSSST VSQRRKRISS TSSLVKSSVS VPSESHPLST INQEAPQPTA TSTKEKQPCS DRYRIYKAQK LREMLKEELR KEKKQWKNKY AINESQRPPD RSKMTMRDFI YYLPDNNPMT SSLEQEKKTE KPSTPVQTRE QEGKSTPNAE DNEMEEETDD GPLLVPRVKV AEDGSIILDE ESLTVEVLRT KGPCVVEEND PIFERGSTTT YSSFRKNYYS KPWSNKETDM FFLAISMVGT DFSMIGQLFP HRARIEIKNK FKREEKTNGW RIDKAFQEKR PFDFDFFAHL LQKVLAEEEK RKQKSVKNHS LKEKKSTKPR KNVKVKKVAC EGVNNDPDES MSSRISDTER SQKDAQTVEE ESLTLSREDA EQVALEVDLN QKKRRRKKQD GANELGVNNL LENATVQAGP SKGEKHKNKC QAIRPELKEG ECSKEQMLSC TQNIDGIVGF ASTEKVEKRT DPILSLSNQQ DATSVATESS ESSTSDLPSF EVGIRALCEV NNAEGSCIEE RNVDLKNNSL EIDQTENVKP MLRGRFQRPK PNLSRAGKKS VLSQGKTESE SKNSHSKTSV EKNHVEKDKM NTLDILRMET TERENPEAET VSVLGEKNCL QEGSQLKALR PVQVRGRLQK PKPNAGKAAE RKEILISQEE IGANVEKNEN ESCADRDTPQ HMEDQSRKDF EEEDVILQPE KNDSFQNVQP DEPKVLNECL SVQENNKANK LNQVPILRTR FQKPKPNIGR GTGRREISSK EEVLEKILVS GEMAAALRET VRLDTSPKEM VPAEINTKEM QSDLKETGRR AISPREKILD VIDDTIEMET GLKAMGREIC LREKTPEVID ATEEIDKDLE EAGRREISPQ KNGPEEVKPL GEVETDLKAT GNESSPREKT PEVTDATEEI DKNLEETGRR KISPRENGPE EVKPVDEMET DLNATGRESS PREKTPEVID ATEEIDLEET EREVSPQENG LEEVKPLGEM ETDLKATGRD SFPRGKTPEV IDAIEEIEID LEETEREISP QENGLEEVKP LGEMQTDLKA TGREISPREK TPEVIDATEE IDKDLEETGR REISPEENGP EEVKPVDEME TDLKTTGREG SSREKTREVI DAAEVIETDL EETEREISPQ ENGPEEVKPV GKMETDLKEI REEISQREKV LAEFSAIREK EIDLKETGKR DIPIMEKVSG KMAVVEEMEA DLKETGKENF RERGSEEICV TEEKVAELKQ TGKTDISPRE NELEETSTSR QTDTHLMQSG SNDFSAVPSL DIQNISSEVL SMMHTPVEEK RNSEKEVSSH FSHFKISSQT HESDKTEVQG IQSPDVPEQF SDINLSKSLP QEQKPLEIKP APFVRSRFKR PKPNLARAAL KRETTESEKY IYEKKSETKK METIVMQENN EQTDTLPSQH DEASLMISRE KDTLGHRNEE AVILPCTQTE RNLSPSNSCE PKEESQSAPV QKNDSVVSVG TNNVNTFQQE MKESVIQTAR QVRGRLQRPR PNIRKTGQRQ IVDKGEAKGI IKEGRTILPK DETEKKVLTV SNSQIETEIE VPSSAVPEHR MYENQSQVVL VENLHVNKTN ETIRHENKPY VPSSAQMTRR KFQKAKPNLG RAHSKKEEPV LEKVTTDQSK EGKPEDHLLQ KGASNTQLLL KEKAELLTSL EVSARKDCVG SKESALAKID AELEEVGPSR RVGEETVGDN SPSSVVEEQY LNKLTSCPQP LNETSYSKIA LDGKTTISST SEYERNRGER RSHKKFKPNV TRGRGSKRVR GKTSKKEPRA SKAMLVTLRA SQEEDDDADD FESDYEEESY HLAPEEVNKA PVFVPVGLRS PEPVSAQIEE TMEELEITVN VPDVGCIAVV EHELPNTDVT TEEMKQEENL SVPFEMTTSE HIQDEPGTND GSTEAAITLL TMGDLVLQSE ISSEQGDVGV CIIPHVHSKD KSHIPSSLDN VNHKIVHECQ ELSSPVITTS PASFEENKIV LEEQSSREEI SLMEKVKENA TPTRNTISKV TSNLRIRSRL AKPKPNLEKT LGTNRLDDYQ EVSSLCVTKG AEMETQRETE KNASKATELE NKNLGPVTTA ENKDQSKLAC VHGIKGTSIS SEVNLTERNE NQEESSQEVH MLSVAPVASS ETGPCTLGLD RGLGENSVEE PQIKDSKGDS VLTLPVPEYT PTSIPEVQQE NIINPQDLTV NLVANVPQDG EDEQAFILTL VEIPANAVEE FTDATAQFMP NPLLPAPILV KSVNTEERGD MSICLPATSV GQDAMGLSIS GRDNSKKPPD NLDLVSRKRF QCRLDKNDHI PPAKKRSLTL RDDCQEYTTE VHSKELTNVF EETGESHKGQ DIFLTSGSTL TTPEPQRQQV EAAFQSRGSR SPDACMDKNV PQLPQDEMIV SDKEERTDAA PKSQQMDSRT SSSKASLSRP GRRPLGFLSL ICSKNSLESD EPMQVHSKKR LKPLIPGLRK KLKRSNPFNE SQEKNRESSD LLPSPSVITT QSENISSSAT QVSCDQPLLK EGYKSAQKRA PQGEATTVSE YFFNDIFIEV DETE

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with BDP1?

The strongest Open Targets associations for BDP1 are neurodegenerative disease, hearing loss, autosomal recessive, aspartate aminotransferase measurement, deafness and Hearing impairment.

How long is the BDP1 protein?

The Homo sapiens BDP1 protein (UniProt A6H8Y1) is 2624 amino acids long.

Browse: Targets: B · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB A6H8Y1 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB A6H8Y1 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.